TP53 and nasopharyngeal carcinoma: Beuvink et al, (2005) reported that everolimus could sensitise cells to cisplatin by inhibiting induction of p21 expression by p53. Ma et al, (2010) showed that everolimus exerts an additive-to-synergetic effect on cisplatin-induced growth inhibition in nasopharyngeal carcinoma.